InfuSystem Holdings, Inc. Reports Higher Fourth Quarter 2012 Revenues and Second Straight Quarterly

Updated

InfuSystem Holdings, Inc. Reports Higher Fourth Quarter 2012 Revenues and Second Straight Quarterly Profit

Company Improves Liquidity Position

MADISON HEIGHTS, Mich.--(BUSINESS WIRE)-- InfuSystem Holdings, Inc. (NYSE MKT: INFU) ("InfuSystem" or the "Company"), a leading national provider of infusion pumps and related services for the healthcare industry in the United States, today reported its second consecutive quarter of profitability in the fourth quarter ending December 31, 2012.


Net income in the fourth quarter was $0.2 million, equal to $0.01 per diluted share, compared to a $0.8 million net loss, or $0.04 loss per diluted share, in the prior year period. For the full year ended December 31, 2012, the Company's net loss was $1.5 million, or $0.07 per diluted share, versus a net loss of $45.4 million, or $2.16 per diluted share, in 2011. The prior- year period included a $67.6 million asset impairment charge.

Gross profit for the three months ending December 31, 2012, was $12.0 million, up 48% from $8.1 million in the fourth quarter of 2011. Gross profit for the full year 2012 was $42.9 million, an increase of 21% compared to $35.4 million in 2011.

Revenues in the fourth quarter were $16.2 million, up 16% from $14.0 million in the fourth quarter of 2011. Total revenues for the year ended December 31, 2012, were $58.8 million, an 8% improvement from $54.6 million in 2011. The increase in revenues is primarily related to the addition of larger customers, increased penetration into existing customer accounts, and the resolution of the oncology drug shortage from 2011. Also, during the fourth quarter of 2012, a major group of third party payors revised their claim processing guidelines that affected all durable medical equipment providers, which pushed some claims to be billed at higher out-of-network rates directly to patients.

SG&A increased to $10.4 million from $8.8 million, in addition to other expenses of $1.2 million compared with $0.5 million of other income a year ago. Adjusted EBITDA for the latest quarter was $3.8 million, up from the $1.5 million for the prior-year period, as adjusted on a comparable basis.

"We are very pleased with our improved fourth quarter performance and fiscal year-over-year growth for the Company," said Dilip Singh, Interim Chief Executive Officer. "The Company has accumulated annualized cost-savings of approximately $1.6 million since the current management team took control in April of 2012. That, combined with our securing a new debt facility during the fourth quarter, has helped restore the Company's liquidity and create a far stronger balance sheet. Equally important, we have generated sufficient momentum to increase the number of third-party payor relationships and expand our provider footprint while delivering best in class service and patient satisfaction. Our efforts are now clearly focused on sustaining long-term growth," Singh added.

Operating Results

Gross profit for the year ended December 31, 2012 was $42.9 million, an increase of 21% compared to $35.4 million in the prior year. It represented 73% of revenues in the current year compared to 65% in the prior year. The increase in the gross margin as a percentage of revenue in 2012 was primarily related to the increase in rental revenue, specifically third party billings, which generally have a higher gross profit margin.

Selling and marketing expenses were $9.9 million compared to $9.4 million for the year ended December 31, 2011. The increase in selling and marketing expenses is primarily related to expenses incurred by the increase in associated revenues as well as increased retention and travel costs. Compared to the prior year, these expenses remained consistent at 17% of revenues.

During the year ended December 31, 2012, general and administrative expenses were $23.1 million, compared to $18.0 million for the year ended December 31, 2011. General and administrative expenses have increased from 33% to 39% of revenues for the year ended December 31, 2012 compared to the same period in the prior year. The increase was primarily due to an increase in professional service costs related to the Concerned Stockholder Group. Additional legal, accounting and outside service fees of $2.2 million were incurred during the year relating to this matter and the related early extinguishment of debt; severance payments for the former CEO amounted to $1.0 million; $0.6 million was recorded for retention payments to key employees during this ongoing matter; and we incurred $0.6 million associated with our decision to evaluate potential strategic alternatives.

Additional increases were mainly attributed to an increase in finance and accounting staff and several other general and administrative accounts. These costs were partially offset by the reversal of previously recognized stock compensation expense of $1.4 million.

Adjusted EBITDA was $13.1 million for the latest fiscal year. This compares to 2011's adjusted EBITDA, adjusted on a comparable basis, of $10.3 million. The Company utilizes Adjusted EBITDA as a means to measure its operating performance. A reconciliation from Adjusted EBITDA, a non-GAAP measure, to net income can be found in the appendix.

Financial Condition

Net cash provided by operations for fiscal 2012 was $5.5 million, down from the $6.7 million for the prior year. This decrease is mainly attributed to higher accounts receivable levels due to the higher revenue in the fourth quarter of 2012. As of December 31, 2012, we had cash and cash equivalents of $2.3 million and $4.7 million of availability on the revolving line-of-credit compared to $0.8 million and $4.9 million of availability on the revolving line-of-credit at December 31, 2011. This increase is due to the new credit facility and better cash management during the year.

Conference Call

The Company will conduct a conference call for investors on Thursday, March 28, 2013 at 9:00 a.m. Eastern Time to discuss fourth quarter performance and results. Dilip Singh, Interim Chief Executive Officer, and Jonathan P. Foster, Chief Financial Officer, will discuss the Company's financial performance and answer questions from the financial community. To participate in this call, please dial in toll-free (888) 895-5479 and use the confirmation number 34394082.

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services to hospitals, oncology practices and other alternate site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, and Ontario, Canada. The Company's stock is traded on the NYSE MKT under the symbol INFU.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. These risks and uncertainties include general economic conditions, as well as other risks, detailed from time to time in the Company's publicly filed documents.

Additional information about InfuSystem Holdings, Inc. is available atwww.infusystem.com.

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

December 31,

December 31,

(in thousands, except share data)

2012

2011

ASSETS

Current Assets:

Cash and cash equivalents

$

2,326

$

799

Accounts receivable, less allowance for doubtful accounts of $3,136 and

$1,773 at December 31, 2012 and December 31, 2011, respectively

8,511

7,350

Accounts receivable - related party

-

98

Inventory

1,339

1,309

Other current assets

684

934

Deferred income taxes

1,971

682

Total Current Assets

14,831

11,172

Medical equipment held for sale or rental

2,626

2,013

Medical equipment in rental service, net of accumulated depreciation

13,071

14,732

Property & equipment, net of accumulated depreciation

867

927

Deferred debt issuance costs, net

2,362

421

Intangible assets, net

25,541

28,221

Deferred income taxes

17,806

18,187

Other assets

419

590

Total Assets

$

77,523

$

76,263

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:

Accounts payable

$

2,135

$

4,004

Accounts payable - related party

9

59

Derivative liabilities

-

258

Current portion of long-term debt

3,953

6,576

Other current liabilities

4,098

2,235

Total Current Liabilities

10,195

13,132

Long-term debt, net of current portion

27,315

22,551

Other liabilities

-

415

Total Liabilities

$

37,510

$

36,098

Stockholders' Equity

Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued

-

-

Common stock, $.0001 par value; authorized 200,000,000 shares; issued and outstanding

21,990,000 and 21,802,515, as of December 31, 2012 and issued and outstanding

21,330,235 and 21,132,545 as of December 31, 2011, respectively

2

2

Additional paid-in capital

88,742

87,541

Accumulated other comprehensive loss

-

(136

)

Retained deficit

(48,731

)

(47,242

)

Total Stockholders' Equity

40,013

40,165

Total Liabilities and Stockholders' Equity

$

77,523

$

76,263

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

Three Months Ended

Twelve Months Ended

December 31,

December 31,

(Unaudited)

(in thousands, except share data)

2012

2011

2012

2011

Net revenues:

Rentals

$

14,568

$

11,933

$

53,471

$

46,795

Product sales

1,665

2,109

5,357

7,842

Net revenues

16,233

14,042

58,828

54,637

Cost of revenues:

Cost of revenues - Product, service and supply costs

2,405

2,465

9,165

9,128

Cost of revenues - Pump depreciation and loss on disposal

1,824

3,495

6,752

10,154

Gross profit

12,004

8,082

42,911

35,355

Selling, general and administrative expenses:

Provision for doubtful accounts

2,132

1,066

5,251

4,099

Amortization of intangibles

706

671

2,734

2,662

Asset impairment charges

-

-

-

67,592

Selling and marketing

2,229

2,283

9,864

9,371

General and administrative

5,374

4,759

23,062

17,987

Total selling, general and administrative:

10,441

8,779

40,911

101,711

Operating income (loss)

1,563

(697

)

2,000

(66,356

)

Other income (loss):

Gain on derivatives

-

-

-

83

Interest expense

(1,105

)

(547

)

(3,340

)

(2,193

)

Loss on extinguishment of long term debt

(119

)

-

(671

)

-

Other (expense) income

(7

)

8

(141

)

(111

)

Total other loss

(1,231

)

(539

)

(4,152

)

(2,221

)

Income (loss) before income taxes

332

(1,236

)

(2,152

)

(68,577

)

Income tax (expense) benefit

Advertisement